Close Menu

NEW YORK (GenomeWeb) — Decipher Biosciences — formerly GenomeDx Biosciences — announced today that it has signed an agreement to help Dendreon Pharmaceuticals identify patients who are likely to respond to its prostate cancer therapy Provenge (sipuleucel-T).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.